For research use only. Not for use in humans.

Mosunetuzumab (Anti-CD20 & CD3e)

Synonyms: BTCT4465A Cat.No.A3174 Purity:99%

Mosunetuzumab is a bispecific T-cell-engaging monoclonal antibody that targets CD20 and CD3e, effectively redirecting T cells to eliminate CD20+ malignant B cells. It demonstrates promising efficacy in treating relapsed or refractory follicular lymphoma. MW: 146.72 KD.

Quality Control

Batch: Purity: 99% Protein concentration: 5.286mg/ml Endotoxin Level: ＜1EU/mg

Specificity

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Mosunetuzumab is a bispecific T-cell-engaging monoclonal antibody that targets CD20 and CD3e, effectively redirecting T cells to eliminate CD20+ malignant B cells. It demonstrates promising efficacy in treating relapsed or refractory follicular lymphoma. MW: 146.72 KD.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1905409-39-3
Isotype	human IGg1
Application	mosunetuzumab (Anti-CD20 & CD3e)
Source	CHO
Formulation	1×PBS, pH 6
Storage	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Sellecks selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.